Apple Inc. vs Cardinal Health, Inc.: Strategic Comparison

This in-depth comparison examines Apple Inc. and Cardinal Health, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Apple Inc. on its own, evaluating Cardinal Health, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Apple Inc. and Cardinal Health, Inc. is widest.

On the headline numbers, Apple Inc. reports annual revenue of $416.2B against $222.6B for Cardinal Health, Inc., while their respective market capitalizations stand at $3.50T and $48.2B. Apple Inc. is headquartered in United States and Cardinal Health, Inc. operates from United States, and those different home markets shape how each company competes.

Apple Inc.: They're wrong. That's more annual revenue than Netflix, Spotify, and Adobe combined. The iPhone isn't the product. He runs a toll booth with 2.2 billion active devices passing through it every day. And yet the interesting question isn't how big Apple is. It's how long the model holds when regulators in Brussels and Washington are actively trying to pry open the walled garden that makes all of this work. That sounds cynical, but the numbers bear it out. But here's what the revenue split obscures: the iPhone isn't really a standalone product anymore. The average Apple household owns 3-4 devices. Services: The Real Margin Engine The App Store, where Apple takes 15-30% of every transaction from 1.8 million apps. Apple Music, Apple TV+, Apple Arcade, Apple News+, Fitness+, and the Apple One bundle that packages them together. AppleCare extended warranties. Services gross margins exceed 70%. Hardware margins sit around 36%. Every dollar that shifts from hardware to services makes Apple more profitable without selling a single additional device. That's the compounding engine Wall Street loves. The Supporting Cast They're network glue. The Capital Return Machine This isn't just shareholder friendliness — it's a structural choice. It's in the accumulated weight of 2.2 billion devices, each one generating recurring revenue and raising the cost of departure. You'd need to replicate the hardware, the OS, the chip design, the app network, the retail stores, the privacy brand, and the migration path — simultaneously. Nobody's doing that. But the iPhone's strategic function has shifted. The average iPhone user upgrades every three to four years. The Services relationship, once established, rarely ends. The Act's App Store provisions require Apple to allow alternative payment systems and third-party app stores on iPhones sold in Europe, directly attacking the mechanism by which Apple collects 15-30% of every digital transaction on its platform. It's Huawei. And the reason tells you everything about where Apple is actually vulnerable. In late 2023, the Mate 60 Pro appeared with a 7nm chip nobody in the West expected. By 2025, Huawei reclaimed double-digit smartphone share in China while Apple's share dropped below 15% in the country. It just needs to make Apple irrelevant in the world's largest smartphone market, and it's doing exactly that. They ship more phones, move faster on hardware form factors, and compete across every price tier from $150 to $1,800. The Galaxy S series matches iPhone spec-for-spec most years. Apple wins on captivity. If Gemini can manage your life, write your emails, organize your photos, and anticipate your needs better than anything Apple offers, then iOS stops being the reason you buy an iPhone. You buy whatever runs the best AI. They own the workplace. Apple has never cracked enterprise in a meaningful way. The Mac is tolerated in corporate environments, not preferred. Each attack hits a different wall of the fortress. And Apple's fortress has many walls. Apple doesn't need to win every battle. It needs to avoid losing all of them at the same time. That dip — the only year of revenue decline in over a decade — reflected consumer spending pressure and a challenging PC market. It had no lasting effect. Hardware gross margins run approximately 35-40% on iPhone, lower on Mac and iPad. Services margin differential means every dollar of Services revenue is worth nearly twice the profit of a dollar of hardware revenue. The iPhone revenue concentration — over 50% of total revenue from a single product category — creates structural exposure to any factor that disrupts the two-year replacement cycle: economic recession, geopolitical disruption to Taiwan Semiconductor supply chains, or competitive pressure from Android manufacturers gaining traction in the premium segment. The EU Digital Markets Act already forces Apple to allow sideloading and alternative payment systems in Europe. Epic Games won the right to external payment links. Apple depends on Chinese manufacturing (Foxconn, Pegatron, Luxshare) for the majority of iPhone assembly while simultaneously selling into China for roughly 17% of revenue. If US-China tensions escalate further, Apple faces the nightmare scenario of supply disruption and demand collapse happening at the same time. Then there's the AI gap. Apple shipped. A promise called Apple Intelligence that requires the newest hardware and still can't do half of what ChatGPT does. If consumers decide AI capability matters more than AI privacy, Apple's differentiation becomes a limitation. I'll make it concrete. My family has four iPhones, two MacBooks, an iPad, two Apple Watches, and AirPods for everyone. We have 11 years of photos in iCloud. Our group chats are in iMessage (and yes, the blue bubble thing is real social pressure among teenagers). My wife's health data — menstrual tracking, heart rate history, sleep patterns — lives in HealthKit with no export path to Android. We have $400+ in purchased apps. Family Sharing manages screen time for our kids. Find My tracks our AirTags on luggage and keys. Apple Pay is configured on every device. Switching to Android would take weeks of active migration work, and we'd still lose data. That's a hostage situation dressed up as convenience. And Apple has 2.2 billion devices worth of hostages. Apple's A-series and M-series chips deliver performance-per-watt that Qualcomm and Intel can't match because Apple controls both the hardware and the software stack. The M-series Mac transition wasn't just a spec bump — it gave MacBooks 15-20 hour battery life and silent operation that fundamentally changed what a laptop could be. Privacy has become the cherry on top. Cynical? Maybe. Effective? Absolutely. For consumers who care about data protection, Apple is the only credible choice among the major platforms. Services is the primary lever. Apple Intelligence is the hardware upgrade catalyst. By restricting AI features to iPhone 15 Pro and newer, Apple created artificial obsolescence for 1.5+ billion older devices. If the AI features prove genuinely useful — better Siri, smart summaries, image generation — they could compress the upgrade cycle from 4 years back toward 3. Health is the long game. Apple Watch already does ECG, blood oxygen, crash detection, and fall detection. Non-invasive glucose monitoring — if they crack it — would be the most significant health technology breakthrough in decades and would make Apple Watch medically indispensable for hundreds of millions of diabetics and pre-diabetics worldwide. That's not a product upgrade. That's a category transformation. Tata and Foxconn facilities in India are already assembling iPhones for export. Vision Pro? I'm skeptical in the near term. At $3,499, it's a developer kit priced as a consumer product. The real bet is that spatial computing becomes a platform in 5-7 years, and Apple wants to own the network before it matters. Everything depends on one variable: whether Apple Intelligence becomes genuinely useful before the market decides it's permanently behind in AI. The upgrade cycle compresses as 1.5 billion older iPhones become functionally obsolete. If Apple Intelligence remains a marketing label stapled onto mediocre features — if Siri still can't set two timers reliably while ChatGPT is writing code — then the narrative shifts permanently. Consumers start choosing phones based on AI capability rather than network. The blue bubble loses its grip when the green bubble has a better assistant. The regulatory question matters, but it's secondary. Steve Wozniak had built a computer circuit board that he wanted to share with friends at the Homebrew Computer Club. Steve Jobs saw something different: a product that ordinary people, not just engineers, might want to buy. The Apple I sold 200 units. Apple had found its first killer application. The 1984 Macintosh introduced the graphical user interface to the mass market, drawing on technology developed at Xerox PARC that Jobs had seen and recognized as defining before Xerox understood what it had. The Mac was expensive, partially closed, and initially sold in limited volumes. These aren't independent businesses. Tim Cook became CEO in 2011, inheriting the company Steve Jobs had rebuilt from near-insolvency in the late 1990s. App Store revenue is the highest-margin component of the highest-margin segment in the company. Huawei doesn't need to beat Apple globally. That's tens of billions in incremental iPhone revenue without acquiring a single new customer. Apple cannot survive being perceived as the company that missed the most important technology transition since mobile. Wozniak and Jobs retained the company. VisiCalc, the first spreadsheet software, ran on the Apple II and created the business case for personal computers in commercial settings. Jobs was forced out of the company by the board in 1985.

Cardinal Health, Inc.: This is not a paradox: the OptumRx contract was generating below-average margins, and its departure actually improved Cardinal Health's overall profitability profile. The volume is enormous. These specialty platforms serve physician practices directly, bypassing the commodity dynamics of wholesale distribution. It is a small fraction of total revenue and an outsized fraction of strategic value. The pivot was well-timed. The U.S. Pharmaceutical market was beginning a structural expansion driven by demographic aging and pharmaceutical innovation that would continue for decades. Walter spent the 1980s and 1990s systematically acquiring pharmaceutical distributors across the country, consolidating a fragmented industry into an oligopoly. The opioid crisis left a significant mark. The reputational and financial costs were substantial. In 1979, he made the pivot, acquiring Ellicott Drug and beginning the transformation into a pharmaceutical company.

Apple Inc. and Cardinal Health, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Apple Inc. and Cardinal Health, Inc..

Apple Inc. business model: It's a subscription business disguised as a consumer electronics brand — one that happens to sell the most profitable physical objects ever manufactured. And it runs at 70%+ gross margins, nearly double what the hardware earns. It's the customer acquisition cost for a lifetime of App Store commissions, iCloud storage fees, AppleCare renewals, and a $20 billion annual check from Google just to remain the default search engine. The company designs and sells iPhone, Mac, iPad, Apple Watch, AirPods, and a growing services portfolio. It's a distribution mechanism for everything else Apple sells. Yet each one deepens the data gravity that makes switching to Android feel like moving countries. ICloud subscriptions from hundreds of millions of users who didn't realize 5GB of free storage would fill up in three months. Apple Pay transaction fees. It's the entry point into a services relationship that generates App Store commissions, iCloud subscriptions, Apple Music fees, Apple TV+ subscriptions, and Apple Pay transaction revenue across a lifetime that typically spans decades. In premium markets, captivity pays better. It needs to make Apple's software feel outdated. It's the European Commission. Each ruling chips away at the 15-30% commission structure that makes Services so obscenely profitable. What Apple has is something more like gravity — the accumulated pull of years of personal investment that makes leaving feel physically painful. It makes a $1,599 MacBook Pro feel safe because Genius Bar exists. Physical retail builds trust for premium pricing in a way that Amazon product pages never will. The Google Search deal ($20B+/year), App Store commissions, iCloud upsells, and the Apple One bundle all compound as the installed base grows. Apple can survive paying smaller App Store commissions.

Cardinal Health, Inc. business model: The oligopoly structure also creates pricing power with generic manufacturers, as the three wholesalers collectively purchase the vast majority of generic drugs sold in the United States. The core mechanism is pharmaceutical distribution: the company purchases branded, generic, and specialty pharmaceutical products from manufacturers at negotiated prices, holds inventory in national distribution centers, and sells to retail pharmacy chains, independent pharmacies, hospital networks, mail-order facilities, long-term care facilities, and other healthcare providers. Revenue is recognized at the point of delivery, and gross profit is the difference between the selling price and the cost of products sold, plus fees for distribution services, data reporting, and value-added programs. Second, generic pharmaceutical pricing is volatile and generally deflationary. Third, branded pharmaceutical distribution generates fees rather than product margin. Under distribution service agreements with branded manufacturers, Cardinal Health receives fees for providing distribution, inventory management, data reporting, and other services. These fees are generally stable and less volatile than generic pricing, but they are subject to renegotiation and competitive pressure. Pricing is constrained by the transparency of generic drug costs and the negotiating power of large customers (CVS, Walgreens, hospital systems, PBMs), but the oligopoly structure prevents the destructive price competition that would occur in a fragmented market. Reimbursement pressures on pharmacy and provider customers have led to an emphasis on reducing drug costs, which flows directly back to distributors in the form of pricing pressure, fee compression, and demands for enhanced services at no additional cost. The company also faces risks from GLP-1 drug pattern: while demand for GLP-1 medications (used for diabetes and obesity treatment) has driven revenue growth, these products did not meaningfully contribute to segment profit in fiscal 2024 due to pricing and reimbursement structures. The company cannot grow profits indefinitely through volume alone — eventually, the market saturates, and pricing pressure intensifies. The strategic logic is that by positioning deeper in the care delivery chain — at the physician practice level — Cardinal Health can capture more value from the pharmaceutical supply chain and generate higher-margin, recurring revenues that are less susceptible to the pricing pressure affecting pure distribution. Potential drug pricing legislation at the federal or state level could affect distributor margins, though the oligopoly structure provides some protection. The 340B drug pricing program, which requires manufacturers to provide discounts to certain healthcare providers, creates complexity in distribution pricing that distributors must navigate. The continued growth of GLP-1 drugs for diabetes and obesity creates volume opportunity but also pricing and reimbursement uncertainty.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Apple Inc. stack up against those of Cardinal Health, Inc..

Apple Inc. competitive advantage: The M-series chips gave MacBooks a genuine performance and battery advantage that Intel never could. Notice something odd about this model: it's almost impossible to compete with because the advantage isn't in any single product. Drop the word "moat" for a moment. That's not a moat. The silicon advantage is the technical layer underneath. The privacy angle transforms from limitation to advantage.

Cardinal Health, Inc. competitive advantage: That dynamic, counterintuitive to anyone who evaluates companies by top-line scale, explains everything important about pharmaceutical wholesale economics. The logic was identical to food distribution — logistics infrastructure, inventory management, and working capital efficiency — but the margins were more stable and the regulatory barriers to entry were higher. The FDA regulations, radiation safety requirements, and half-life constraints — some doses decay meaningfully within hours — create barriers to entry that no competitor has successfully navigated at similar scale. The nuclear pharmacy business merits specific attention: operating the nation's largest network of nuclear pharmacies at margins substantially above the distribution average, with competitive moats built on FDA licensing, radiation safety expertise, and time-sensitive logistics, Cardinal Health holds a genuinely difficult-to-replicate position in a niche that grows with diagnostic imaging demand. The financial architecture reveals a business with razor-thin margins that generates substantial absolute profits through enormous scale. This business requires specialized regulatory compliance, short half-life logistics, and clinical expertise that create significant barriers to entry. The cost structure reflects the scale-intensive nature of the business. The cost structure shows the scale-intensive nature of the business. Cardinal Health's single most defensible competitive moat is its position as one of three companies controlling over 90% of the U.S. Pharmaceutical wholesale market, creating an oligopoly structure with barriers to entry that new competitors cannot overcome within a decade. This market concentration provides three specific, data-backed competitive advantages. First, scale purchasing power with generic pharmaceutical manufacturers. This business has significant barriers to entry due to FDA regulations, radiation safety requirements, and the clinical expertise needed to compound radioactive doses. The network's scale creates a competitive moat: hospitals and imaging centers depend on reliable, on-time delivery of radiopharmaceuticals, and switching suppliers involves significant operational risk. The strategic acquisitions in specialty care — ION in oncology, GI Alliance in gastroenterology, ADSG in diabetes, and Solaris Health in urology — are building a physician-facing services platform that could create a new competitive moat. If successful, this platform could create switching costs for physicians who rely on Cardinal Health's integrated services (practice management, drug procurement, patient support, reimbursement assistance) and generate higher-margin, recurring revenues. The financial scale of Cardinal Health provides a further competitive advantage. The company's network of nuclear pharmacies provides time-critical radiopharmaceutical doses to hospitals and imaging centers, a service with significant barriers to entry and stable demand. Nuclear and Precision Health Solutions benefits from an aging population requiring more diagnostic imaging, the expansion of therapeutic radiopharmaceuticals (particularly in oncology), and the inherent barriers to entry in nuclear pharmacy. Cardinal eventually spun off the medical distribution business, returning to pharmaceutical focus — a decision that reflected the greater profitability and scale advantages available in pharmaceutical distribution at the time.

Future prospects matter as much as current results. The growth strategies below explain how Apple Inc. and Cardinal Health, Inc. each plan to expand from here.

Apple Inc. growth strategy: Apple doesn't need the cash for operations, and reducing share count mechanically increases earnings per share even when revenue growth slows. The company's blended margins improve as Services grows faster than hardware. The buyback program has been one of the most effective capital return mechanisms in corporate history, compounding per-share earnings growth beyond what operating income growth alone would produce. You can't diversify away from China in three years when your supply chain took twenty years to build. That wasn't an accident — it was Apple weaponizing privacy as a competitive tool while simultaneously building its own advertising business. Apple's growth playbook under Tim Cook comes down to one idea: make each existing customer worth more money every year without requiring them to buy a new phone. India and manufacturing diversification serve dual purposes: reducing China risk and opening a growth market. India's middle class is expanding, 5G infrastructure is improving, and Apple's brand aspirational value is enormous there.

Cardinal Health, Inc. growth strategy: The specialty oncology acquisitions tell a more interesting story about where Cardinal Health is investing for growth. The 2025 decline from the OptumRx exit is temporary relative to the growth trajectory. The company has responded to the OptumRx loss with an aggressive acquisition strategy. The company has pursued an aggressive acquisition strategy including Integrated Oncology Network, GI Alliance, Advanced Diabetes Supply Group, and Solaris Health to diversify into higher-margin healthcare services. The segment profit growth of 12% in fiscal 2025, despite a 3% revenue decline, demonstrates the company's ability to improve profitability through product mix shifts — specifically, growth in higher-margin branded and specialty pharmaceuticals and BioPharma Solutions services that offset the OptumRx contract loss. The 'Other' businesses represent Cardinal Health's highest-margin operations and its strategic growth vector. Fourth, specialty pharmaceuticals — including oncology, rheumatology, urology, and plasma products — represent a growth area with higher margins than traditional distribution. The company has invested heavily in specialty pharmacy capabilities, patient support programs, and consulting services for manufacturers. The problem is, McKesson has pursued a similar strategy with its McKesson Specialty Health and Biologics businesses, but Cardinal Health's acquisitions in oncology (ION), gastroenterology (GI Alliance), and urology (Solaris Health) represent a more concentrated bet on physician-facing services. Cencora has focused more on specialty pharmaceutical distribution and international expansion (particularly through its acquisition of Alliance Healthcare). Excluding the OptumRx impact, revenue increased 18%, demonstrating strong underlying growth in the remaining business. The decline reflects the OptumRx contract expiration, partially offset by branded and specialty pharmaceutical growth from existing and new customers. The margin improvement reflects cost improvement initiatives and growth from existing customers. The most immediate threat to Cardinal Health's margin and market position is the structural pressure on pharmaceutical wholesale margins from a healthcare system increasingly focused on cost containment. The generic drug market, which has been a significant profit driver for distributors through price appreciation and new launch margins, has experienced persistent deflation as FDA approvals have flooded the market with competing products. Compliance with DSCSA and other regulations requires significant technology investment. The segment's 1.07% profit margin in fiscal 2025, while improved from prior years, remains insufficient to justify significant capital investment. This logistics network requires billions in capital investment, sophisticated inventory management systems, regulatory compliance infrastructure (including DSCSA track-and-trace), and relationships with thousands of local pharmacies and healthcare facilities. By owning or partnering with physician practices, Cardinal Health positions itself deeper in the care delivery chain, capturing value from drug administration, patient support, and care coordination rather than just product distribution. Cardinal Health's growth strategy under CEO Jason Hollar rests on four specific, named initiatives with measurable targets: (1) growing Pharmaceutical and Specialty Solutions segment profit at a 4-6% compound annual growth rate through product mix improvement and specialty pharmaceutical expansion; (2) building a diversified specialty care platform through acquisitions in oncology, gastroenterology, diabetes, and urology; (3) expanding the highest-margin 'Other' businesses including Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics; and (4) maintaining adjusted free cash flow of approximately $2 billion annually to fund acquisitions, share repurchases, and debt reduction. The Pharmaceutical and Specialty Solutions segment profit growth target of 4-6% CAGR is the core financial objective. This growth is expected to come from several sources: increased contribution from branded pharmaceutical and specialty pharmaceutical products, which carry higher margins than generic distribution; growth from BioPharma Solutions, including Specialty Networks that provide consulting, patient support, and data services to manufacturers and providers; and the accretive impact of recent acquisitions. The specialty care platform strategy is the most far-reaching initiative. The Nuclear and Precision Health Solutions growth strategy targets the expanding diagnostic and therapeutic radiopharmaceutical market. The expansion of therapeutic radiopharmaceuticals, particularly in oncology (e.g. Lutathera for neuroendocrine tumors, Pluvicto for prostate cancer), creates new growth opportunities. The at-Home Solutions strategy addresses the shift toward home-based care. The capital allocation strategy is equally specific. These targets imply that management believes the company can achieve sustained earnings growth even in a challenging revenue environment. The Pharmaceutical and Specialty Solutions segment remains the revenue engine, but its growth will be measured in profit improvement rather than top-line expansion. The segment's 1.07% profit margin, while improved from 0.74% in fiscal 2024, remains insufficient to justify significant capital investment. Management has executed cost improvement initiatives that improved profitability, but structural challenges — manufacturing cost inflation, competition from lower-cost international producers, and hospital purchasing consolidation — persist. The 'Other' businesses represent the highest-growth, highest-margin opportunity. Cencora's international expansion and specialty focus represent a third strategic path. The Drug Supply Chain Security Act (DSCSA) full implementation requires continued technology investment. Walter observed that the pharmaceutical distribution industry was growing rapidly as hospitals and retail druggists increased their orders, while the grocery business stagnated. In 1979, he acquired Bailey Drug Co. a pharmaceutical distributor in Zanesville, Ohio, and renamed the company Cardinal Distribution Inc. Yet the cardinal theme, inspired by Ohio's state bird, would carry through all subsequent ventures. Walter's acquisition strategy was distinctive: he sought companies with proven track records and deep local customer relationships, then allowed them to continue operating largely autonomously under the Cardinal umbrella. This decentralized approach preserved the acquired companies' customer relationships and institutional knowledge while providing them with Cardinal's capital and infrastructure. By 1988, the company had grown sufficiently that Walter sold the remaining food operations to Roundy's Inc. freeing Cardinal to focus entirely on pharmaceutical distribution. The company's name was changed to Cardinal Health in 1994 to reflect its expanding mission beyond pure distribution. In 1995, Cardinal acquired Medicine Shoppe International, the country's largest franchise of retail pharmacies. In 1996, the company acquired Pyxis Corp. a manufacturer of automated supply and pharmaceutical dispensing systems for hospitals. In 1997, Cardinal acquired Owen Healthcare, a provider of outsourced management services for hospital pharmacies and materials management departments. In 1998, the company acquired R.P. Scherer Corp. a developer of drug delivery systems, and formed Cardinal MarketFORCE to recruit sales and marketing teams for pharmaceutical manufacturers. The 2000s continued the acquisition-driven growth. In 2001, Cardinal acquired Bindley Western Industries, a pharmaceutical distributor. In 2006, the company acquired ParMed Pharmaceutical, adding generic pharmaceutical distribution capabilities. In 2007, Cardinal acquired VIASYS Healthcare, adding respiratory and neurological diagnostic products. In 2010, the company acquired Healthcare Solutions Holding, expanding its specialty pharmaceutical services. This partnership has been critical to Cardinal Health's competitive position in generic pharmaceuticals. In 2017, Cardinal Health acquired the Patient Recovery business from Medtronic for $6.1 billion, expanding its medical products portfolio. In 2021, the company acquired Hellman & Friedman for its remaining interest in naviHealth, a post-acute care management company. Despite this challenge, Cardinal Health has continued to execute its strategy, raising guidance and pursuing acquisitions to diversify into higher-margin healthcare services. He was ambitious and operationally focused, and he recognized quickly that food distribution — high volume, thin margins, intense logistics — had structural similarities to pharmaceutical distribution that most people were not seeing. Cardinal Distribution went public in 1983, providing capital to accelerate the acquisition strategy that would define the company's growth. The company has since invested heavily in compliance infrastructure while continuing to build out its specialty pharmacy and services businesses.

A closer look at the financial trajectory of Apple Inc. and Cardinal Health, Inc. rounds out the comparison.

Apple Inc.: Apple reported FY2025 net sales of $416.2 billion and net income of $112.0 billion. Products generated $307.0 billion of net sales, while Services reached $109.2 billion and carried a 75.4% gross margin. The financial story is no longer only iPhone unit growth: Services, custom silicon, share repurchases, installed-base retention, and ecosystem monetization have become central to Apple's profit model.

Cardinal Health, Inc.: Cardinal Health generated $222.578 billion in fiscal 2025 revenue, down from $226.827 billion in fiscal 2024, mainly because the OptumRx pharmaceutical distribution contract expired in June 2024. The revenue decline was strategically unusual: losing a very large but low-margin contract reduced sales while improving the mix of the remaining business. Net earnings were $1.569 billion in fiscal 2025. The key operating question is whether Cardinal can convert its scale in pharmaceutical distribution into more durable profit through specialty care, medical products, at-home solutions, and services layered on top of the core wholesale network.